Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.17 USD | -1.12% | -8.18% | +9.20% |
Sales 2024 * | 26.34M 36M | Sales 2025 * | 21.24M 29.04M | Capitalization | 423M 579M |
---|---|---|---|---|---|
Net income 2024 * | -139M -190M | Net income 2025 * | -154M -211M | EV / Sales 2024 * | 6.42 x |
Net cash position 2024 * | 254M 347M | Net cash position 2025 * | 244M 333M | EV / Sales 2025 * | 8.46 x |
P/E ratio 2024 * |
-3.2
x | P/E ratio 2025 * |
-3.1
x | Employees | 145 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.38% |
Latest transcript on C4 Therapeutics, Inc.
1 day | -1.12% | ||
1 week | -8.18% | ||
Current month | -24.48% | ||
1 month | -22.29% | ||
3 months | +12.80% | ||
6 months | +331.47% | ||
Current year | +9.20% |
Managers | Title | Age | Since |
---|---|---|---|
Andrew Hirsch
CEO | Chief Executive Officer | 53 | 20-09-13 |
Kendra Adams
DFI | Director of Finance/CFO | 48 | 20-11-19 |
Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bruce Downey
CHM | Chairman | 76 | 15-11-30 |
Glenn Dubin
BRD | Director/Board Member | 67 | 21-03-11 |
Bihua Chen
PRN | Corporate Officer/Principal | 55 | 15-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 6.17 | -1.12% | 1,047,766 |
24-04-25 | 6.24 | -3.55% | 1,418,552 |
24-04-24 | 6.47 | -6.23% | 1,039,528 |
24-04-23 | 6.9 | +0.58% | 911,665 |
24-04-22 | 6.86 | +2.08% | 746,871 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.20% | 423M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- CCCC Stock